Cloning and cell viability analysis showed that enhanced FoxK2 expression sensitized McF-7 breast cancer cells to paclitaxel or epirubicin treatment while depletion of FoxK2 through small interfering RNA (siRNA) resulted in resistance. Here, FOXK2 is linked to breast carcinoma.